» Articles » PMID: 30776417

HLA-A*32:01 is Strongly Associated with Vancomycin-induced Drug Reaction with Eosinophilia and Systemic Symptoms

Abstract

Background: Vancomycin is a prevalent cause of the severe hypersensitivity syndrome drug reaction with eosinophilia and systemic symptoms (DRESS), which leads to significant morbidity and mortality and commonly occurs in the setting of combination antibiotic therapy, affecting future treatment choices. Variations in HLA class I in particular have been associated with serious T cell-mediated adverse drug reactions, which has led to preventive screening strategies for some drugs.

Objective: We sought to determine whether variation in the HLA region is associated with vancomycin-induced DRESS.

Methods: Probable vancomycin-induced DRESS cases were matched 1:2 with tolerant control subjects based on sex, race, and age by using BioVU, Vanderbilt's deidentified electronic health record database. Associations between DRESS and carriage of HLA class I and II alleles were assessed by means of conditional logistic regression. An extended sample set from BioVU was used to conduct a time-to-event analysis of those exposed to vancomycin with and without the identified HLA risk allele.

Results: Twenty-three subjects met the inclusion criteria for vancomycin-associated DRESS. Nineteen (82.6%) of 23 cases carried HLA-A*32:01 compared with 0 (0%) of 46 of the matched vancomycin-tolerant control subjects (P = 1 × 10) and 6.3% of the BioVU population (n = 54,249, P = 2 × 10). Time-to-event analysis of DRESS development during vancomycin treatment among the HLA-A*32:01-positive group indicated that 19.2% had DRESS and did so within 4 weeks.

Conclusions: HLA-A*32:01 is strongly associated with vancomycin-induced DRESS in a population of predominantly European ancestry. HLA-A*32:01 testing could improve antibiotic safety, help implicate vancomycin as the causal drug, and preserve future treatment options with coadministered antibiotics.

Citing Articles

Single-cell immunopathology of recurrent acute generalized exanthematous pustulosis associated with vancomycin.

Mukherjee E, Gibson A, Krantz M, Gangula R, Palubinsky A, Boyd A J Allergy Clin Immunol Glob. 2025; 4(2):100426.

PMID: 40008097 PMC: 11851205. DOI: 10.1016/j.jacig.2025.100426.


Vancomycin Drug Reaction with Eosinophilia and Systemic Symptoms: Meta-Analysis and Pharmacovigilance Study.

Aboukaoud M, Adi Y, Abu-Shakra M, Morhi Y, Agbaria R J Clin Med. 2025; 14(3).

PMID: 39941601 PMC: 11818417. DOI: 10.3390/jcm14030930.


Fatal outcome related to drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis of FAERS database and a systematic review of cases.

Liang C, An P, Zhang Y, Liu X, Zhang B Front Immunol. 2024; 15:1490334.

PMID: 39737180 PMC: 11683082. DOI: 10.3389/fimmu.2024.1490334.


A Rare Case of Vancomycin-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

Mallick D, Kaushik N, Goyal L, Chandramohan D, Simhadri P, Singh P Cureus. 2024; 16(11):e73088.

PMID: 39650900 PMC: 11620993. DOI: 10.7759/cureus.73088.


The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) - Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions.

James F, Goh M, Vogrin S, Ng I, Douglas A, Holmes N World Allergy Organ J. 2024; 17(8):100936.

PMID: 39211425 PMC: 11357849. DOI: 10.1016/j.waojou.2024.100936.


References
1.
Illing P, Vivian J, Dudek N, Kostenko L, Chen Z, Bharadwaj M . Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012; 486(7404):554-8. DOI: 10.1038/nature11147. View

2.
Rapin N, Hoof I, Lund O, Nielsen M . MHC motif viewer. Immunogenetics. 2008; 60(12):759-65. PMC: 2613509. DOI: 10.1007/s00251-008-0330-2. View

3.
Gragert L, Madbouly A, Freeman J, Maiers M . Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Hum Immunol. 2013; 74(10):1313-20. DOI: 10.1016/j.humimm.2013.06.025. View

4.
Empedrad R, Darter A, Earl H, Gruchalla R . Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol. 2003; 112(3):629-30. DOI: 10.1016/s0091-6749(03)01783-4. View

5.
Trubiano J, Strautins K, Redwood A, Pavlos R, Konvinse K, Aung A . The Combined Utility of Ex Vivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions. J Allergy Clin Immunol Pract. 2017; 6(4):1287-1296.e1. PMC: 5930120. DOI: 10.1016/j.jaip.2017.09.004. View